Shares of Celyad SA (NASDAQ:CYAD) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.
Analysts have set a 1 year consensus price target of $74.00 for the company, according to Zacks. Zacks has also given Celyad an industry rank of 101 out of 265 based on the ratings given to related companies.
Separately, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $49.00 target price (up from $35.00) on shares of Celyad in a research report on Friday, September 1st.
Celyad (NASDAQ:CYAD) traded down $0.20 during trading hours on Tuesday, hitting $44.45. 303 shares of the stock traded hands, compared to its average volume of 2,756. Celyad has a 12-month low of $16.73 and a 12-month high of $64.75.
ILLEGAL ACTIVITY WARNING: This report was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.dispatchtribunal.com/2017/12/07/zacks-analysts-set-74-00-price-target-for-celyad-sa-cyad.html.
Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company’s product, C-Cure, allows the differentiation of a patient’s own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle.
Get a free copy of the Zacks research report on Celyad (CYAD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celyad SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad SA and related companies with MarketBeat.com's FREE daily email newsletter.